Spots Global Cancer Trial Database for CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Official Title: Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment
Study ID: NCT00186680
Conditions
Study Description
Brief Summary: Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Detailed Description: Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide \& Cisplatin for Stage IV Breast Cancer \& Limited Prior Treatment
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford University School of Medicine, Stanford, California, United States
Contact Details
Name: Ginna Laport
Affiliation: Stanford University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
